Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Lung Cancer

Lung cancer is a common and very serious form of cancer, with more than 40,000 people diagnosed with the condition each year in the UK. The symptoms of lung cancer do not present in the early stages, but when symptoms do eventually present, they usually include the following:

Lung Cancer and Electrolyte Imbalances

Pulmonary Resection in Lung Cancer

Exploring Diversity in Lung Cancer: Impact on Incidence, Prognosis, and Treatment Strategies

Lung Cancer Questions

Lung Plethysmography Procedure

Lung Cancer: Radiotherapy and Chemotherapy

Secondary Lung Cancer

Lymph Nodes in Lung Cancer

Lung Cancer Diagnosis

Lung Cancer Screening Procedure

Pulmonary Transplant (Lung Transplant)

See more featured articles »

Palliative and End-of-Life Care in Lung Cancer

Lung Cancer Risk Factors

Carcinogens in Cigarette Smoke

Lung Cancer Genetics

What Causes Lung Cancer in Non-Smokers?

Lung Cancer Causes

How to Prevent Lung Cancer

Types of Lung Cancer Surgery

Everything You Need to Know About Giving Up Cigarettes

Epidemiology of Lung Cancer

Lung Cancer Treatments

Lung Cancer in Women: Understanding the Increasing Risk

Lung Cancer Symptoms

What are the Survival Rates for Lung Cancer?

Lung Cancer Pathogenesis

Immunotherapy: The Future of Lung Cancer Treatment?

Lung Cancer Research

Latest Lung Cancer News and Research

Leveraging the power of T cells for more effective and durable cancer immunotherapies

T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main goal in immunotherapy.

24 Oct 2025

How COVID mRNA vaccines may make cancer treatments more effective

Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were linked to significantly longer survival in lung and melanoma cancer patients. The vaccines trigger a powerful type-I interferon response that primes tumors to become more responsive to immunotherapy.

23 Oct 2025

Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR high complexity assays

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad's Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad's QX600 platform.

23 Oct 2025

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

‘Cancer doesn’t care’: Citizen lobbyists unite to push past Washington’s ugly politics

Mary Catherine Johnson is a retired small-business owner from outside Rochester, New York. She voted for Donald Trump three times.

21 Oct 2025

Digital health program increases lung cancer screening rates in high-risk individuals

A new study led by researchers at Wake Forest University School of Medicine, in collaboration with the University of North Carolina at Chapel Hill and MD Anderson Cancer Center, has found that a direct-to-patient digital health program can significantly increase lung cancer screening rates among people at high risk.

20 Oct 2025

CRATERs identified as key sites for T cell-mediated tumor destruction

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing. These craters could serve as good markers for immunotherapy success.

17 Oct 2025

Scientists discover why a powerful leukemia drug fails in most patients

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance.

17 Oct 2025

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.

17 Oct 2025

Blocking key protein restores healthy lung function and reduces fibrosis in mice

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to deliver oxygen to the body.

16 Oct 2025

Thymic health found to predict immunotherapy success in cancer patients

The health of the thymus - a key part of the body's immune system - is associated with cancer patients' outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international study reported at ESMO 2025.

16 Oct 2025

Mobile van brings advanced lung cancer screening to New Yorkers

A state-of-the-art health screening van launched this month is bringing advanced imaging technology and health education directly to New Yorkers who are at the greatest risk of developing lung cancer.

16 Oct 2025

Study provides a roadmap for how health systems can improve lung cancer screening rates

Lung cancer screening might be the best-kept secret in health care today. Only about 16 percent of those who are eligible in the U.S. get screened for lung cancer, but a study coming out in NEJM Catalyst on Wednesday provides a roadmap for how health systems can improve those numbers.

15 Oct 2025

Quitting smoking after cancer diagnosis sharply improves survival, study finds

Postdiagnosis smoking cessation was linked to significantly longer overall survival among cancer patients across all stages, based on real-world electronic health record data. Despite clear survival benefits, only one in five smokers quit within six months of diagnosis, highlighting missed opportunities for intervention.

13 Oct 2025

University Of California researchers, patients wary of Trump cuts even as some dollars flow again

In August, an 80-year-old woman walked into the emergency room at Ronald Reagan UCLA Medical Center. She was lucid but experiencing a stroke.

9 Oct 2025

Housing support programs tied to improved cancer detection among seniors

A new study led by researchers from the Johns Hopkins Bloomberg School of Public Health found that older adults receiving federal housing assistance were on average diagnosed at earlier stages with three common cancers-colon, breast, and non-small cell lung-compared to peer cancer patients who were not receiving assistance.

8 Oct 2025

NCCN enhances widely used breast cancer guidelines with advanced digital features

Today, the National Comprehensive Cancer Network® (NCCN®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familial high-risk assessment, during Breast Cancer Awareness Month.

7 Oct 2025

IASLC proposes new tumor budding-based grading system for lung squamous cell carcinoma

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, targetable molecular alterations.

6 Oct 2025

Bio-Rad extends partnership with Gencurix through strategic agreement for Droplet Digital™ PCR IVD oncology kits in Europe

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix' CE-IVD Droplex™ digital PCR oncology testing kits throughout Europe.

3 Oct 2025